Sei Investments Co. Sells 10,165 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Sei Investments Co. lessened its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 263,582 shares of the biotechnology company's stock after selling 10,165 shares during the period. Sei Investments Co. owned about 0.43% of Ascendis Pharma A/S worth $36,287,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB bought a new position in shares of Ascendis Pharma A/S during the 3rd quarter worth about $30,000. Jones Financial Companies Lllp lifted its stake in Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 197 shares during the period. Blue Trust Inc. boosted its holdings in Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 328 shares in the last quarter. Groupama Asset Managment bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at approximately $60,000. Finally, GAMMA Investing LLC raised its holdings in shares of Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after buying an additional 214 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

NASDAQ:ASND traded down $3.26 on Friday, hitting $154.68. 289,067 shares of the stock were exchanged, compared to its average volume of 465,825. The stock has a market capitalization of $9.39 billion, a price-to-earnings ratio of -21.79 and a beta of 0.62. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $169.37. The company's 50-day moving average price is $144.16 and its 200 day moving average price is $137.01.

Remove Ads

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, equities research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on ASND shares. Evercore ISI boosted their price target on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research note on Tuesday, February 18th. JPMorgan Chase & Co. upped their target price on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, March 18th. The Goldman Sachs Group boosted their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. Finally, UBS Group assumed coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a "buy" rating and a $196.00 target price for the company. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat.com, Ascendis Pharma A/S has an average rating of "Moderate Buy" and an average target price of $204.64.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.